RDInvesting Provides Investors with Free In-Depth Equity Reports on AZN, CGIX, HSTM and LH


Follow this company

Companies Mentioned

NYSE:AZN / NASDAQ:CGIX / NASDAQ:HSTM / NYSE:LH
04/02/2014 [ACCESSWIRE]

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.

AstraZeneca plc (NYSE: AZN) shares increased 0.77 percent to close at $65.38 a share Tuesday. The stock traded between $65.02 and $11.72 on volume of 981,108 shares traded. Analysts at Panmure have recently upgraded the company's rating to "hold" from "sell". Shares of AstraZeneca have gained approximately 10.0 percent year-to-date.

Find out more about AstraZeneca including full access to the free equity report at:     
www.RDInvesting.com/AZN

Cancer Genetics Inc. (NASDAQ: CGIX) shares increased 3.98 percent to close at $15.69 a share Tuesday. The stock traded between $15.45 and $16.69 on volume of 194,708 shares traded. Analysts at Cantor Fitzgerald have recently initiated coverage on the company with a "buy" rating and a price target of $21.00. Shares of Cancer Genetics have gained approximately 14.0 percent year-to-date.

Find out more about Cancer Genetics including full access to the free equity report at:        
www.RDInvesting.com/CGIX

HealthStream, Inc. (NASDAQ: HSTM) shares increased 1.50 percent to close at $27.10 a share Tuesday. The stock traded between $26.65 and $27.85 on volume of 347,812 shares traded. Analysts at Noble Financial have recently upgraded the company's rating to "buy" from "hold". Shares of HealthStream have fallen approximately 16.0 percent year-to-date.

Find out more about HealthStream including full access to the free equity report at:       
www.RDInvesting.com/HSTM

Laboratory Corp. of America Holdings (NYSE: LH) shares increased 4.13 percent to close at $102.27 a share Tuesday. The stock traded between $99.74 and $102.65 on volume of 2.43 million shares traded. Analysts at UBS have recently upgraded the company's rating to "buy" from "neutral". Shares of Laboratory Corp. have gained approximately 12.0 percent year-to-date.

Find out more about Laboratory Corp. including full access to the free equity report at:       
www.RDInvesting.com/LH

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:           
Research Driven Investing    
info@rdinvesting.com

COMMENTS

Leave a comment...
 * 

Your Name
 *